M
Michael Teneriello
Researcher at Texas Oncology
Publications - 27
Citations - 2602
Michael Teneriello is an academic researcher from Texas Oncology. The author has contributed to research in topics: Carboplatin & Gemcitabine. The author has an hindex of 15, co-authored 26 publications receiving 2293 citations. Previous affiliations of Michael Teneriello include Drexel University & Uniformed Services University of the Health Sciences.
Papers
More filters
Journal ArticleDOI
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian,Stephanie V. Blank,Barbara A. Goff,Patricia L. Judson,Michael Teneriello,Amreen Husain,Mika A. Sovak,Jing Yi,Lawrence R. Nycum +8 more
TL;DR: GC plus BV followed by BV until progression resulted in a statistically significant improvement in PFS compared with GC plus PL in platinum-sensitive ROC, and the primary end point was progression-free survival by RECIST.
Journal ArticleDOI
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
David G. Mutch,M. Orlando,T. Goss,Michael Teneriello,Alan N. Gordon,Scott McMeekin,Yanping Wang,Dennis R. Scribner,Martin Marciniack,R. Wendel Naumann,Angeles Alvarez Secord +10 more
TL;DR: Although this was not designed as an equivalency study, gemcitabine and PLD seem to have a comparable therapeutic index in this population of Pt-R taxane-pretreated OC patients, and single-agent gem citabine may be an acceptable alternative to PLD for patients with Pt- R OC.
Journal Article
p53 and Ki-ras Gene Mutations in Epithelial Ovarian Neoplasms
Michael Teneriello,Masahito Ebina,R. I. Linnoila,M. Henry,John D. Nash,Robert C. Park,Michael J. Birrer +6 more
TL;DR: The pattern of Ki-ras and p53 mutations appears to distinguish LMP tumors from invasive carcinomas and suggests that they may be separate biological entities.
Journal ArticleDOI
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann,Robert L. Coleman,Robert A. Burger,Edward A. Sausville,Elzbieta Kutarska,Sharad A. Ghamande,Nashat Y. Gabrail,Stephen E. DePasquale,Elżbieta Nowara,Lucy Gilbert,Robert H. Gersh,Michael Teneriello,Wael A. Harb,Panagiotis A. Konstantinopoulos,Richard T. Penson,James T. Symanowski,Chandra D. Lovejoy,Christopher P. Leamon,David Morgenstern,Richard A. Messmann +19 more
TL;DR: Vintafolide plus PLD is the first combination to demonstrate an improvement over standard therapy in a randomized trial of patients with platinum-resistant ovarian cancer.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
Ignace Vergote,Deborah K. Armstrong,Giovanni Scambia,Michael Teneriello,Jalid Sehouli,Charles Schweizer,Susan C. Weil,Aristotelis Bamias,Keiichi Fujiwara,Kazunori Ochiai,Christopher J. Poole,Vera Gorbunova,Wenquan Wang,Daniel J. O'Shannessy,Thomas J. Herzog +14 more
TL;DR: Neither farletuzumab dose met the study's primary PFS end point, but prespecified subgroup analyses demonstrated that patients with CA-125 levels not more than three times the upper limit of normal (ULN) and patients with higher farletsumab exposure showed superior PFS and OS compared with placebo.